Company Overview
Pharmaceutical company in Australia, New Zealand, Malaysia and Singapore with sales of $85M.
Development company with USA filings or planned filings for unique acetaminophen and ibuprofen combination analgesic (tablet, oral liquid, intravenous). First USA approvals due soon
Development company with novel orphan dermatology drug in development. Approved IND and ODD. Clinicals underway
Development company with novel high performance nasal drug delivery system capable of delivering multiple drugs through a patented ultrasonic drug delivery mechanism. Already approved IA and further approvals to follow

******* Late stage in-licensing opportunities for USA for oral and IV analgesics with opioid sparing advantages **************


******* Dermatology Orphan Drug Partnership opportunity in a significant market *************